June 23, 2021
Ono Pharmaceutical said on June 21 that its PD-1 inhibitor Opdivo (nivolumab) obtained a label expansion allowing its combination use with Avastin (bevacizumab) and chemotherapy for the treatment of unresectable, advanced or recurrent non-small cell lung cancer (NSCLC). The updated...read more